CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 76% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English

Trade Galectin Therapeutics Inc. - GALT CFD

1.8965
0%
  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
  • Ownership
Trading Conditions
Spread 0.0370
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.026151 %
Charges from full value of position ($-4.97)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.026151%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee 0.003929 %
Charges from full value of position ($0.75)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.003929%
Overnight fee time 21:00 (UTC)
Min traded quantity 1
Currency USD
Margin 5%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

Galectin Therapeutics Inc ESG Risk Ratings

High Medium Low Negligible

‘D’ score indicates poor relative ESG performance and insufficient degree of transparency in reporting material ESG data publicly.

More ESG coverage

Key Stats
Prev. Close* 1.8965
Open* 1.9465
1-Year Change* 20.9%
Day's Range* 1.8665 - 1.9465
52 wk Range 1.02-2.47
Average Volume (10 days) 26.52K
Average Volume (3 months) 1.20M
Market Cap 104.87M
P/E Ratio -100.00K
Shares Outstanding 59.58M
Revenue N/A
EPS -0.67
Dividend (Yield %) N/A
Beta 1.33
Next Earnings Date Nov 13, 2023

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Sep 29, 2023 1.8965 0.0600 3.27% 1.8365 1.9065 1.8265
Sep 28, 2023 1.8965 0.1300 7.36% 1.7665 1.8965 1.7665
Sep 27, 2023 1.8065 -0.0100 -0.55% 1.8165 1.8265 1.7665
Sep 26, 2023 1.7965 -0.0300 -1.64% 1.8265 1.8565 1.7765
Sep 25, 2023 1.8365 -0.0200 -1.08% 1.8565 1.8665 1.7665
Sep 22, 2023 1.7465 0.0300 1.75% 1.7165 1.7765 1.6665
Sep 21, 2023 1.7665 0.0300 1.73% 1.7365 1.7765 1.6965
Sep 20, 2023 1.7765 -0.0800 -4.31% 1.8565 1.9165 1.7465
Sep 19, 2023 1.9165 0.0700 3.79% 1.8465 1.9365 1.8465
Sep 18, 2023 1.9365 0.1600 9.01% 1.7765 1.9565 1.7765
Sep 15, 2023 1.7565 -0.1400 -7.38% 1.8965 1.9065 1.7365
Sep 14, 2023 1.9065 -0.0600 -3.05% 1.9665 1.9665 1.8765
Sep 13, 2023 1.9065 0.0800 4.38% 1.8265 1.9365 1.7865
Sep 12, 2023 1.7865 0.1400 8.50% 1.6465 1.8065 1.6465
Sep 11, 2023 1.6665 0.0400 2.46% 1.6265 1.6765 1.6265
Sep 8, 2023 1.7160 0.0100 0.59% 1.7060 1.7360 1.7060
Sep 7, 2023 1.7360 0.1000 6.11% 1.6360 1.7460 1.6360
Sep 6, 2023 1.6360 -0.0400 -2.39% 1.6760 1.6760 1.6260
Sep 5, 2023 1.6960 -0.0500 -2.86% 1.7460 1.7560 1.6360
Sep 1, 2023 1.7560 0.0800 4.77% 1.6760 1.7560 1.6560

Galectin Therapeutics Inc. Events

Time (UTC) Country Event
Monday, November 13, 2023

Time (UTC)

13:30

Country

US

Event

Q3 2023 Galectin Therapeutics Inc Earnings Release
Q3 2023 Galectin Therapeutics Inc Earnings Release

Forecast

-

Previous

-
Friday, December 1, 2023

Time (UTC)

16:00

Country

US

Event

Galectin Therapeutics Inc Annual Shareholders Meeting
Galectin Therapeutics Inc Annual Shareholders Meeting

Forecast

-

Previous

-
View all events
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total revenue 0 0 0 0 0
Total Operating Expense 38.352 30.179 23.444 13.438 13.602
Selling/General/Admin. Expenses, Total 6.615 6.361 5.468 5.971 7.131
Research & Development 31.737 23.818 17.976 7.467 6.471
Operating Income -38.352 -30.179 -23.444 -13.438 -13.602
Interest Income (Expense), Net Non-Operating -0.424 -0.348 -0.021 0.144 -0.298
Net Income Before Taxes -38.776 -30.527 -23.465 -13.294 -13.9
Net Income After Taxes -38.776 -30.527 -23.465 -13.294 -13.9
Net Income Before Extra. Items -38.776 -30.527 -23.465 -13.294 -13.9
Net Income -38.776 -30.527 -23.465 -13.294 -13.9
Total Adjustments to Net Income -0.097 -0.171 -0.137 -6.885 -1.147
Income Available to Common Excl. Extra. Items -38.873 -30.698 -23.602 -20.179 -15.047
Income Available to Common Incl. Extra. Items -38.873 -30.698 -23.602 -20.179 -15.047
Diluted Net Income -38.873 -30.698 -23.602 -20.179 -15.047
Diluted Weighted Average Shares 59.391 58.527 57.029 52.238 39.414
Diluted EPS Excluding Extraordinary Items -0.65453 -0.52451 -0.41386 -0.38629 -0.38177
Diluted Normalized EPS -0.65453 -0.52451 -0.41386 -0.38629 -0.38177
Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
Total revenue 0 0 0 0 0
Total Operating Expense 9.003 10.342 10.633 8.122 9.662
Selling/General/Admin. Expenses, Total 1.632 1.543 1.626 1.524 1.588
Research & Development 7.371 8.799 9.007 6.598 8.074
Operating Income -9.003 -10.342 -10.633 -8.122 -9.662
Interest Income (Expense), Net Non-Operating -0.111 -1.185 -0.001 -0.475 0.049
Net Income Before Taxes -9.114 -11.527 -10.634 -8.597 -9.613
Net Income After Taxes -9.114 -11.527 -10.634 -8.597 -9.613
Net Income Before Extra. Items -9.114 -11.527 -10.634 -8.597 -9.613
Net Income -9.114 -11.527 -10.634 -8.597 -9.613
Total Adjustments to Net Income -0.063 0 -0.065 0.016 -0.064
Income Available to Common Excl. Extra. Items -9.177 -11.527 -10.699 -8.581 -9.677
Income Available to Common Incl. Extra. Items -9.177 -11.527 -10.699 -8.581 -9.677
Diluted Net Income -9.177 -11.527 -10.699 -8.581 -9.677
Diluted Weighted Average Shares 59.582 59.48 59.424 59.396 59.389
Diluted EPS Excluding Extraordinary Items -0.15402 -0.1938 -0.18005 -0.14447 -0.16294
Dividends per Share - Common Stock Primary Issue 0 0 0 0
Diluted Normalized EPS -0.15402 -0.1938 -0.18005 -0.14447 -0.16294
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total Current Assets 20.552 41.82 29.465 48.209 8.832
Cash and Short Term Investments 18.592 39.648 27.142 47.48 8.253
Cash & Equivalents 18.592 39.648 27.142 47.48 8.253
Prepaid Expenses 1.96 2.172 2.323 0.729 0.579
Total Assets 21.285 41.827 29.6 48.467 9.006
Property/Plant/Equipment, Total - Net 0.086 0.007 0.048 0.084 0
Property/Plant/Equipment, Total - Gross 0.081 0.122 0.158 0.074
Accumulated Depreciation, Total -0.074 -0.074 -0.074 -0.074
Intangibles, Net 0
Total Current Liabilities 13.012 9.033 5.399 2.82 2.108
Accounts Payable 3.89 1.805 1.292 1.661 0.297
Accrued Expenses 9.058 7.163 4.042 1.093 1.512
Notes Payable/Short Term Debt 0 0 0 0 0
Other Current Liabilities, Total 0.064 0.065 0.065 0.066 0.299
Total Liabilities 53.479 39.211 5.407 2.872 2.108
Total Long Term Debt 39.828 29.048 0 0 0
Total Equity -32.194 2.616 24.193 45.595 6.898
Redeemable Preferred Stock 2.233 2.25 2.25 2.26 2.26
Preferred Stock - Non Redeemable, Net 6.682
Common Stock 0.059 0.059 0.056 0.056 0.041
Additional Paid-In Capital 275.081 271.001 261.883 259.673 194.13
Retained Earnings (Accumulated Deficit) -309.567 -270.694 -239.996 -216.394 -196.215
Total Liabilities & Shareholders’ Equity 21.285 41.827 29.6 48.467 9.006
Total Common Shares Outstanding 59.426 59.3413 57.0771 56.8946 41.1909
Total Preferred Shares Outstanding 1.26018 1.30268 1.30268 1.32768 6.83568
Other Long Term Assets, Total 0.647 0.087 0.174 0.174
Other Liabilities, Total 0.639 1.13 0.008 0.052
Long Term Debt 39.828 29.048
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Total Current Assets 19.552 20.552 17.121 25.785 33.507
Cash and Short Term Investments 17.799 18.592 15.831 24.178 31.606
Cash & Equivalents 17.799 18.592 15.831 24.178 31.606
Prepaid Expenses 1.753 1.96 1.29 1.607 1.901
Total Assets 20.225 21.285 17.914 25.886 33.615
Property/Plant/Equipment, Total - Net 0.078 0.086 0.093 0.101 0.108
Other Long Term Assets, Total 0.595 0.647 0.7
Total Current Liabilities 11.533 13.012 9.588 10.892 9.535
Accounts Payable 2.553 3.89 2.352 2.964 1.906
Accrued Expenses 8.98 9.058 7.236 7.864 7.629
Notes Payable/Short Term Debt 0 0 0 0 0
Other Current Liabilities, Total 0 0.064 0 0.064 0
Total Liabilities 62.871 53.479 40.249 41.109 39.808
Total Long Term Debt 49.941 39.828 29.734 29.504 29.275
Other Liabilities, Total 1.397 0.639 0.927 0.713 0.998
Total Equity -42.646 -32.194 -22.335 -15.223 -6.193
Redeemable Preferred Stock 2.233 2.233 2.233 2.233 2.25
Common Stock 0.059 0.059 0.059 0.059 0.059
Additional Paid-In Capital 276.156 275.081 274.241 272.772 272.108
Retained Earnings (Accumulated Deficit) -321.094 -309.567 -298.868 -290.287 -280.61
Total Liabilities & Shareholders’ Equity 20.225 21.285 17.914 25.886 33.615
Total Common Shares Outstanding 59.5822 59.426 59.426 59.3958 59.3885
Total Preferred Shares Outstanding 1.26018 1.26018 1.26018 1.26018 1.30268
Long Term Debt 49.941 39.828 29.734 29.504 29.275
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Net income/Starting Line -38.776 -30.527 -23.465 -13.294 -13.9
Cash From Operating Activities -31.056 -24.308 -20.601 -10.848 -10.179
Cash From Operating Activities 0
Non-Cash Items 2.752 2.468 1.922 1.805 4.793
Changes in Working Capital 4.968 3.751 0.942 0.641 -1.072
Cash From Investing Activities 0 0 0
Capital Expenditures 0
Cash From Financing Activities 10 36.814 0.263 50.075 15.379
Issuance (Retirement) of Stock, Net 0 6.814 0.263 50.469 15.379
Net Change in Cash -21.056 12.506 -20.338 39.227 5.2
Total Cash Dividends Paid 0 -0.394
Other Investing Cash Flow Items, Total 0 0
Issuance (Retirement) of Debt, Net 10 30
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Net income/Starting Line -11.527 -38.776 -28.142 -19.545 -9.932
Cash From Operating Activities -10.793 -31.056 -23.817 -15.47 -8.042
Non-Cash Items 1.607 2.752 2.206 1.176 0.719
Changes in Working Capital -0.873 4.968 2.119 2.899 1.171
Cash From Financing Activities 10 10 0 0 0
Issuance (Retirement) of Stock, Net 0 0 0 0
Net Change in Cash -0.793 -21.056 -23.817 -15.47 -8.042
Issuance (Retirement) of Debt, Net 10 10 0 0
Cash From Investing Activities 0
Other Investing Cash Flow Items, Total 0

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Galectin Therapeutics Inc. Company profile

About Galectin Therapeutics Inc

Galectin Therapeutics Inc. is a biotechnology company that is focused on developing novel therapies to improve the lives of patients with chronic liver disease and cancer. The Company’s product candidates include galectin-3 inhibitor, belapectin (GR-MD-02) and GM-CT-01. The Company’s lead drug belapectin is a carbohydrate-based drug that inhibits the galectin-3 protein which is directly involved in multiple inflammatory, fibrotic, and malignant diseases. The Company is using a galectin-3 inhibitor to treat advanced liver fibrosis and liver cirrhosis in non-alcoholic steatohepatitis patients. The Company also designed a Phase IIb/II clinical study, the NAVIGATE trial, evaluating the safety and efficacy of its galectin-3 inhibitor, belapectin (GR-MD-02), for the prevention of esophageal varices in patients with non-alcoholic steatohepatitis (NASH) cirrhosis.

Financial summary

BRIEF: For the nine months ended 30 September 2021, Galectin Therapeutics Inc revenues was not reported. Net loss applicable to common stockholders increased 49% to $23.4M. Higher net loss reflects Research and development increase of 58% to $17.7M (expense), Other General and administrative increase of 15% to $3.6M (expense), Stock-based Compensation in SGA increase of 38% to $1.2M (expense).

Equity composition

Common Stock $.001 Par, 03/12, 300M auth., 12,842,850 issd. Insiders own 18.44%. Ser. A Pref. Stock 5M auth., 1,592,500 issd. Redeemable convt. Pref. stock Ser. B-1 900,000 auth., 900,000 issd. Ser. B-2 2.1M auth., 2,100,000 issd. PO 12/13/01, 1,428,572 shares @ $3.50by Atlas Capital Services LLC. 03/12. 1-for-6 Reverse split.

Industry: Biotechnology & Medical Research (NEC)

Suite 240
4960 Peachtree Industrial Boulevard
NORCROSS
GEORGIA 30071
US

Income Statement

  • Annual
  • Quarterly

News

How to Trade The Triple Top

Welcome to Part 5 of our 7-part Power Patterns series. In this series, we'll be equipping you with the skills to trade some of the most indicative price patterns which occur on any timeframe in every market.

14:13, 27 September 2023
USA flag on the background of stock charts. Financial system in USA

Q4 lookahead: US indices starting to show signs of trouble?

US indices start to draw attention as traders focus on the outlook for Q4.

07:20, 27 September 2023

USD/JPY Climbs Towards Key Highs

USDJPY’s powerful long-term uptrend has been reignited after last week’s sharply contrasting policy statements from the Federal Reserve and Bank of Japan.

11:32, 26 September 2023

EUR/USD tests key support

EUR/USD is currently testing a key support level after the Federal Reserve indicated a potential extension of higher interest rates.

14:32, 21 September 2023
Bank of England building

BoE leaves rates unchanged, GBP drops further as investors look for more clarity

The Bank of England has left rates unchanged at 5.25% with a 5-4 vote split after CPI dropped more than expected in August

11:45, 21 September 2023
British banknotes and coins photographed directly above. The coins are in a stack, placed on top of the banknotes.

GBP softer after CPI surprise, JPY focused on any further hints from Ueda

GBP drops after a softer CPI reading scares investors about the BoE intentions. JPY on the lookout for further policy tweaks from Governor Ueda.

12:42, 20 September 2023

How to Trade The Break & Retest

In this week's instalment, we delve into the Break & Retest pattern—a strategic approach to navigating breakout trades. If you've wrestled with the frustration of false breakouts, incorporating this pattern into your trading toolkit may help you overcome this challenge and put you on the path to becoming a more confident and consistent trader.

11:59, 20 September 2023

People also watch

BTC/USD

28,094.15 Price
+3.340% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 85.00

Oil - Crude

88.26 Price
-1.830% 1D Chg, %
Long position overnight fee 0.0584%
Short position overnight fee -0.0803%
Overnight fee time 21:00 (UTC)
Spread 0.030

XRP/USD

0.53 Price
+0.120% 1D Chg, %
Long position overnight fee -0.0753%
Short position overnight fee 0.0069%
Overnight fee time 21:00 (UTC)
Spread 0.01192

Gold

1,832.05 Price
-0.920% 1D Chg, %
Long position overnight fee -0.0195%
Short position overnight fee 0.0113%
Overnight fee time 21:00 (UTC)
Spread 0.30

Still looking for a broker you can trust?

Join the 555.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading